文献速递甲状腺疾病

多模式治疗未分化甲状腺癌患者的PD-1与PD-L1表达:一项回顾性研究结果

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

这项单机构回顾性队列研究纳入16例接受调强放疗(其中15例先行手术)的未分化甲状腺癌患者,检测PD-1/PD-L1表达与生存的关联。炎症细胞PD-1高表达(>40%染色)与更差的总生存相关(HR 3.36,95%CI 1.00–12.96,P<0.05),肿瘤细胞PD-L1高表达(>33%染色)与更差的PFS和OS呈趋势相关。

要点

  • 所有样本炎症细胞均表达PD-1,肿瘤细胞主要为阴性。
  • 多数样本肿瘤细胞表达PD-L1,以膜染色为主。
  • 炎症细胞PD-1>40%染色与更差OS相关(HR 3.36,P<0.05)。

核心结论

  • PD-1/PD-L1通路蛋白在未分化甲状腺癌肿瘤样本中高表达,似乎可作为多模式治疗患者PFS和OS的预测标志物。

研究设计与样本

  • 单机构回顾性队列研究,纳入16例接受调强放疗的患者(其中15例先行手术),患者均接受统一的多模式治疗。

主要发现

  • 所有样本炎症细胞均显示PD-1表达,而肿瘤细胞主要为阴性。
  • 多数样本肿瘤细胞表达PD-L1,且主要为膜染色。
  • 炎症细胞PD-1高表达(>40%染色)与更差的总生存相关(HR 3.36,95%CI 1.00–12.96,P<0.05),并呈更差PFS的趋势。
  • 肿瘤细胞PD-L1高表达(>33%染色)与更差PFS和OS呈趋势相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Anaplastic thyroid cancer (ATC) is rare and a highly fatal malignancy. The role of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) as prognostic and/or predictive markers in ATC is unknown. OBJECTIVE: Multimodal therapy offers the best chance at tumor control. The objective of this study was to detect potential associations of PD-1/PD-L1 axis variables with outcome data in ATC. DESIGN: Retrospective study of a uniformly treated cohort. SETTING: Single institution retrospective cohort study. PATIENTS OR OTHER PARTICIPANTS: Sixteen patients who received intensity-modulated radiation therapy (15 had preceding surgery) were studied. MAIN OUTCOME MEASURE: Patients treated with multimodal therapy were followed and assessed for overall survival (OS) and progression-free survival (PFS). RESULTS: All samples demonstrated PD-1 expression in inflammatory cells whereas tumor cells were primarily negative. PD-L1 was expressed on ATC tumor cells in most samples and showed mainly membranous staining. High PD-1 expression (>40% staining) in inflammatory cells was associated with worse overall survival (OS; hazard ratio, 3.36; 95% confidence interval, 1.00 to 12.96; P < 0.05) and trended toward worse PFS, whereas high PD-L1 expression in tumor cells (>33% staining) trended toward worse PFS and OS. CONCLUSION: PD-1/PD-L1 pathway proteins are highly expressed in ATC tumor samples and appear to represent predictive markers of PFS and OS in multimodality-treated ATC patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chintakuntlawar AV, Rumilla KM, Smith CY, et al. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. J Clin Endocrinol Metab. 2017. PMID: 28324060. doi:10.1210/jc.2016-3756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。